GSK plc (GSK)

Executive Summary

GSK plc is a global biopharmaceutical company with a leading portfolio in vaccines, specialty medicines, and general medicines. The company's strategy centers on maximizing the impact of its pipeline, which contains approximately 130 candidates across core therapeutic areas including infectious diseases, HIV, oncology, and immunology. In recent years, GSK has demonstrated strong commercial execution with its RSV vaccine Arexvy, which has quickly become a blockbuster, and its HIV franchise through ViiV Healthcare. The company continues to invest in research and development, with notable late-stage assets in respiratory, infectious diseases, and immunology. Despite facing patent expirations on some established medicines, GSK's pipeline and diversified portfolio position it for sustainable growth. GSK's recent performance has been bolstered by robust vaccine sales and a steady stream of regulatory approvals. The company's focus on innovation and disciplined capital allocation supports its goal of delivering long-term value to shareholders. Key upcoming milestones include potential label expansions for Arexvy and regulatory decisions on new specialty medicines. With a strong balance sheet and a clear strategic direction, GSK is well-positioned to navigate industry challenges and capitalize on emerging opportunities in high-need therapeutic areas.

Upcoming Catalysts (preview)

• Q4 2026Arexvy pediatric approval decision (RSV vaccine)60% success
• Q2 2026Depemokimab (IL-5) regulatory decision for severe asthma70% success
• Q1 2027BLU-5937 (camlipixant) Phase 3 topline results for chronic cough50% success